

Effects of ayahuasca on fear and anxiety: cross-talk between 5HT1A and 5HT2A receptors

Lorena Terene Lopes Guerra¹, Rafael Guimarães dos Santos^{1,2}, and Jaime Eduardo Cecilio Hallak^{1,2}

Ayahuasca is a hallucinogenic substance currently being investigated for the treatment of mood, anxiety, and trauma-related disorders. Evidence from animal and human studies suggest that the effects of ayahuasca involve modulation of neural substrates relevant for emotional processing, especially in regions rich in serotonergic receptors. Moreover, preclinical studies also show that ayahuasca has specific effects on fear-related memories. The serotonergic system has been classically associated to anxiety and fear responses, with selective serotonin reuptake inhibitors being first-class medication to treat mood, anxiety, and stress-related disorders. Here we review currently available data regarding ayahuasca (and its main components) behavioral and functional effects on anxiety and fear-related responses through its modulation of serotonergic signaling.

Psychedelics March 2025;1(2):15–25; doi: <https://doi.org/10.61373/pp024i.0037>

Keywords: Ayahuasca, fear, anxiety, serotonin

Introduction

Ayahuasca (AYA) is a hallucinogenic beverage traditionally consumed by indigenous groups from Northwestern Amazon and, more recently, by syncretic religious groups present worldwide. The main psychoactive compound in AYA is N,N-dimethyltryptamine (DMT), present in the leaves of *Psychotria viridis*, but the preparation of AYA also involves the *Banisteriopsis caapi* vine, rich in β -carbolines (1). The β -carbolines act as antagonists on digestive system monoamine oxidase enzymes that, otherwise, would degrade DMT before it could reach the central nervous system (2). Harmine, tetrahydroharmine, and harmaline are the most relevant β -carbolines in AYA, which have their own pharmacological properties, adding another layer of complexity to the mechanisms of action of AYA (3).

AYA can be defined as a classic hallucinogen, since it has agonistic effects in different serotonergic receptors, especially the 2A subtype (5HT2A receptor) (4). The subjective and hallucinogenic effects of AYA seem to result from its agonism at 5HT2A receptors; however, it can also act on different receptor subtypes, with the 1A receptor (5HT1A) being of special interest for the discussion proposed by this review (5, 6). The effects of AYA on serotonergic pathways mostly rely on DMT action, since β -carbolines present little to no affinity for most serotonergic receptors, except for a modest affinity for the 5HT2A receptor (3, 5).

Similarly to what have been happening to other psychedelic substances, AYA properties have been investigated as treatment for numerous psychiatric disorders, such as depression, anxiety, and substance use disorder (7–11). Additionally, preclinical studies have suggested a possible action of AYA on fear processing circuits, which could support possible mechanism for therapeutic effects on anxiety and posttraumatic stress disorder (PTSD) (12, 13). A few observational studies and case reports have already been published about therapeutic effects of AYA on trauma processing and treatment of PTSD (14, 15), with promising results. Nonetheless, until now, clinical trials performed in controlled settings are lacking.

Apart from serotonin receptors, AYA also has effects on glutamatergic, dopaminergic, and endocannabinoid systems (16–18). It is possible that DMT acts as an agonist of σ -1 receptors (19), which was already suggested as a possible mechanism for AYA effects on fear processing (20).

Moreover, AYA intake can alter neuroendocrine responses as well (21). These complex interactions, however, are beyond the scope of this review. Here, we aimed to concatenate and discuss data regarding AYA effects on fear and anxiety and how it can be associated with its actions on serotonin (5HT) receptors.

Fear Behavior and Anxiety

Fear is an evolutive preserved behavior that acts as a defense mechanism and is usually triggered by threatening and dangerous stimuli. Some stimuli can naturally elicit a defensive behavior, while others can be learned and associated to lifelong responses. This behavioral plasticity is crucial for adaptation to an environment that continuously challenges individuals with new contexts (22). Anxiety, on the other hand, represents a state of increased arousal and vigilance even in the absence of an imminent threat, and it can also elicit behavioral defensive responses (23).

Impairments on appropriate fear and anxiety responses are the cause of a variety of psychiatric disorders, such as PTSD, generalized anxiety and panic disorders (24). Efforts to develop better treatment options for patients suffering from these disorders demand the development of tests and paradigms that can assess the behavioral and neural alterations underlying the symptoms.

Paradigms for Assessing Fear and Anxiety Responses

The more frequently employed paradigms to assess fear and anxiety responses in preclinical studies usually are rooted on inherent behavioral characteristics of the animals or on associative learning of conditioned responses to naturally aversive stimuli.

In the first category, the animal behavior is affected by an approach-avoidance conflict between the inherent tendency for the animal to explore the new environment versus fear-driven behaviors. The elevated plus-maze (EPM) and the open field test (OFT) are two of the most famous tasks based on this premise. Animals expressing increased anxiety-like behavior spend more time on the closed arms (EPM) or in the edges of the field (OFT), respectively. Treatment with anxiolytic drugs increase entrances and time spend on the open arms for the EPM, as well as time spent in the center of the arena for the OFT (25, 26).

On the second category, the classical or Pavlovian conditioning is the most widely employed protocol to study fear behavior and memories.

¹Departamento de Neurociências e Ciências do Comportamento, Universidade de São Paulo, Ribeirão Preto 14015-010, Brazil; ²National Institute of Science and Technology Translational Medicine (INCT-TM) 14015-010, Brazil

Corresponding Author: Prof. Rafael Guimarães dos Santos, Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, Brazil. Phone: +551636350713. E-mail: banisteria@gmail.com
 Received: 9 September 2024. Revised: 28 October 2024 and 12 November 2024. Accepted: 14 November 2024.

Published online: 10 December 2024.





Through this paradigm, a stimulus once neutral, that is, that does not elicit a behavioral response, is paired to a stimulus that naturally evokes a fear response. Once the animal is trained through simultaneous presentations of the latter (that is called the unconditioned stimulus or US) together with the former (which will be called the conditioned stimulus or CS), an associative memory is acquired and the CS alone is able to evoke the behavioral response (27, 28). Alterations in US intensity and CS characteristics can result in memories with different characteristics, like duration, intensity of evoked behavioral response and generalization (22). The two more frequently employed fear conditioning paradigms are the contextual fear conditioning (CFC) and the tone fear conditioning (TFC). Both apply electric shocks at the animal's paw as the US, but the first uses the whole context where the animal is trained as the CS, and the latter uses a specific sound as the CS, and the animal is tested being exposed to the same sound but in a different context from training (29).

Fear conditioning protocols have been widely employed by preclinical researchers as a tool to understand memory formation as well as how they can be altered or forgotten. Repeated re-exposure to the CS is the base for reconsolidation and extinction protocols (30). If elucidating the fear memory formation is relevant, understanding how already established responses can be altered can be even more valuable to contribute for treating disorders like PTSD (31).

In humans, the behavioral and subjective consequences of fear and anxiety are frequently assessed using specifically developed psychometric instruments. However, there are many tasks as well that can be employed, being especially useful when accessing neural alterations underlying the behavioral responses through neuroimaging techniques.

Social cognition tasks frequently employ emotional relevant stimuli. During tasks involving the recognition of emotions in facial expressions (REFE), subjects are presented to static or dynamic images of facial expressions and asked to recognize pictured emotion. There are many variations in these tasks, but several are based on Ekman's theory of basic universal emotions (32). Performance in these tasks seems to be altered by numerous conditions, especially when responding to negative valence emotions, like fear (33–35). Another task example is the Simulation of Public Speaking Test (SPST), an anxiety-induced task where individuals are asked to elaborate a speech on a random matter and present it in front of camera, mimicking a public speak situation (36).

Neural Substrates Underlying Fear and Anxiety Responses

Multiple brain regions are involved on processing of emotionally relevant stimuli, but a significant part of the available data produced in the last decades focuses on understanding cortical-limbic circuits dynamics. In this section, we will focus on prefrontal cortex (PFC), amygdala (AMY), and hippocampus (HPP) influence on fear and anxiety processing. Later (Section 2.3), raphe nuclei innervations to these structures will also be discussed.

Prefrontal Cortex. The PFC is involved in numerous executive processes. It receives and projects to structures relevant to emotional, cognitive, sensory, and motor functioning, resulting in a central integrative role for behavioral control and flexibility, highly influenced by external cues and internal contingencies (37). Although there is an ongoing debate regarding the homologies between rodent and primate composition of the PFC, the medial PFC (mPFC) from rodents holds similarities in the modulation exerted by human dorsolateral, medial and cingulate cortices over memory, emotional regulation and response control, among other functions (38).

The rodent mPFC includes two main subdivisions, the prelimbic cortex (PL), that together with the anterior cingulate cortex constitutes the dorsal mPFC, and the infralimbic cortex (IL), more ventrally located. Despite being closely located and intimately interconnected, these two regions have different projecting profiles (37, 39). The PL have more efferent connections with the basolateral nucleus of the AMY (BLA), and dorsal and median raphe nuclei, while the IL innervates numerous AMY nuclei, but especially the central AMY nucleus (CeA), and the lateral septum (39).

The PL projections, although not necessary for fear conditioning acquisition, are needed for the consolidation of the associative fear memory

(40). The PL is also relevant for freezing expression after TFC, since CS-modulated disinhibition of PL principal neurons (PNs) projections to the BLA is relevant for fear expression during test (41). The IL activity does not influence fear acquisition or consolidation; however, it is essential for fear extinction retention, suggesting a role on behavioral flexibility (42). Optogenetically silencing IL PNs during extinction learning does not interfere with freezing reduction within session, but impaired extinction recall. However, silencing the PNs during extinction test does not impair extinction recall, indicating that proper IL activation is necessary for consolidation of the extinction memory (43).

The mPFC activity exerts a top-down modulation of subcortical structures relevant for emotional regulation (37). Consistent with that, data from clinical and preclinical studies suggest that increased anxiety responses are linked to a hypoactivation of this region, which can also result in impaired cognitive flexibility (44–46). In mice, synchrony between mPFC and BLA activity is related to discrimination of safety contexts during fear learning and anxiety protocols (47). Similarly, when compared with healthy controls, patients with generalized anxiety disorder had reduced ventromedial PFC activation when processing safety signals (48).

Regarding PL and IL, their precise role on modulation of anxiety responses is less well defined, with contrasting results on the literature, that may result from projections' functional heterogeneity (49).

Amygdala. The AMY is a subcortical structure comprising different nuclei and located in the medial temporal lobe. It receives projections from cortical and subcortical structures, essentially acting as an information processing hub that translate sensory inputs to other areas relevant to behavioral control and emotional processing, such as the PFC and HPP (50, 51).

During fear conditioning, the CS and US association depends on an intricate temporal balance of the different AMY nuclei activation (22). The lateral portion of the AMY is the input region for sensory information, and it is also where the CS and US stimuli representations are associated. However, the communication with other AMY nuclei depends on glutamatergic projections leaving from the basal AMY. Since both regions are intimately interconnected, they are often referred as the basolateral AMY (BLA) (52). If the BLA is the main input center, the central AMY (CeA) is the output, projecting to structures relevant for fear expression, such as the hypothalamus and the periaqueductal gray (53). The BLA PNs innervate de CeA directly, but also regulate its activity indirectly through projections to the intercalated cells (ITC), a GABAergic cell mass, that also innervates the CeA (54). AMY activity is necessary for both CFC and TFC, but on the former, the context representation relies on dorsal HPP activity which then indirectly communicates with the AMY through ventral HPP projections (29, 55).

Altered activity in different AMY nuclei is associated to anxiety responses. Inside the AMY, activation of projections from the BLA to CeA have an anxiolytic effect, while selective optogenetic inhibition of these neurons result in an increase of anxiety-like behavior in mice (56). Functional connectivity between these two subregions is also impaired in patients with generalized anxiety disorder (57). When exposed to emotional relevant stimuli, patients with anxiety and trauma-related disorders tend to present increased AMY response (58).

Hippocampus. The HPP is located in the temporal lobe and implicated in multiple cognitive, memory and emotional processing functions. This structure can be functionally differentiated into two distinct areas, the ventral HPP and the dorsal HPP (59).

The dorsal HPP functioning is associated to cognitive performance and is responsible for encoding the representation of the context during CFC, hence why this task is described as HPP-dependent. Lesions on the dorsal HPP impair CFC expression without altering TFC (60).

Additionally, HPP is one of the few structures where new neurons can be born in adult brains (61), although there is an ongoing debate whether this property is present in humans (61, 62). Impaired neurogenesis seems to be related to symptomatology of multiple psychiatric disorders, like depression and PTSD (63).

However, this hippocampal region does not directly project to the AMY and the integrations of context representation to sensory inputs to AMY



depends on ventral HPP projections (64). Added to its role on CFC acquisition, dorsal HPP also is relevant for fear memory recall and extinction (65, 66).

The ventral HPP, on the other hand, is more associated to emotional processing, being the only HPP region projecting directly to AMY (64). Additionally, the ventral HPP also seem to be relevant for expression of anxiety responses. Anxiogenic environments increase synchronization of mPFC and ventral HPP, the same not being reported for the dorsal HPP (67). Additionally, lesions on the ventral HPP lead to decrease in anxiety-like responses in the EPM (68).

In humans, PTSD is associated with decreased HPP volume and impaired HPP activation in women performing a verbal declarative memory task (69), and it is also associated with reduced HPP activation to trauma-related stimuli (70). In patients with generalized anxiety disorder, the anterior HPP (analog to the ventral HPP in rodents) had decreased activation to repeated exposure to threat cues when compared with healthy controls (71).

Serotonin Effects on Fear and Anxiety Responses

Studies on human serotonin receptors are intimately linked to hallucinogenic compounds. In 1953, Gaddum reported lysergic acid diethylamide (LSD) antagonistic effect over 5-HT responses elicited in vitro (72, 73) and, since then, seven serotonin receptor classes have been described, mostly represented by G-protein coupled receptors (74). Although hallucinogenic compounds can interact with different 5HT receptor classes, most of the available data focus on the 5HT₂ and 5HT₁ subtypes, specifically the 2A and 1A subtypes (75).

The 5HT_{2A} subtype is G_{q/11}-coupled and abundantly expressed in cortical areas, especially on layer V dendrites of PNs, which are densely innervated by 5HT axons (76). Their activation mostly produces increased membrane excitability through a slow membrane depolarization and inhibition of calcium activated after-hyperpolarization currents (77).

The 5HT_{1A} receptors, on the other hand, are presynaptically expressed on 5HT neurons of the raphe nuclei where they act as autoreceptors and regulate 5HT release (78). However, they are also widely distributed through substrates relevant to memory and emotional processing, such as the HPP, cingulate and entorhinal cortices and AMY, where they are postsynaptically expressed (79, 80). These receptors are coupled to the G_i protein, and their activation induces membrane hyperpolarization through increase in rectifying potassium currents and inactivation of calcium channels (74, 77).

The seemingly opposing effects of 5HT_{2A} and 1A receptors on membrane potential may appear contradictory as they are often co-expressed on cortical PNs (81), but these differences are relevant for stimuli processing. The hyperpolarizing action of 5HT_{1A} alters the sensibility to input-generated excitability, restraining firing frequency, while the inhibition of after-hyperpolarization induced by 5HT_{2A} activation increases excitability, modulating neuronal gain (77). Apart from PNs, these receptors can be expressed on cortical GABAergic interneurons (INs) as well, adding another layer of complexity to serotonergic control over cortical excitatory/inhibitory balance (76, 81).

Through the 70s and 80s many studies explored how 5HT affected punishment conditioned behaviors. At the time, 5HT signaling pathways were thought to regulate these behaviors and promote punishment-induced response suppression. Although further evidence elucidated that this relationship is not as straightforward as initially thought, 5HT role on fear and anxiety neurobiology is still undeniable, with selective 5HT reuptake inhibitors (SSRIs) being the first line of treatment for many stress and anxiety disorders (24).

The theory formulated by Deakins and Graeff proposes that distinct fear and anxiety behavioral responses are controlled by specific 5HT pathways arising from the raphe nuclei. The dorsal raphe (DRN) periventricular tract is responsible to react to acute US exposure, controlling flight or fight responses, and mostly modulating the periaqueductal gray activity. The DRN forebrain bundle tract (DRD/DRC) is activated by acute exposure to CS and controls avoidance behaviors through projections to structures such as the AMY, ventral HPP and PFC. And the median raphe forebrain bundle tract (DRI/MnR) responds to chronic US and/or CS exposure, being

responsible to promote resilience or tolerance to chronic stress, projecting to the dorsal HPP and PL and IL cortices, acting mostly through postsynaptic 5HT_{1A} activation (82, 83).

Knock-out mice for the 5HT_{2A} receptor present decreased anxiety-like behaviors, but have normal CFC and TFC, and the reestablishment of 5HT_{2A} signaling in cortical neurons normalized the anxiety-like responses (84). In the BLA, activation of 5HT projections of DRN increases anxiety-like responses through 5HT_{2A} activation (85).

Pretreatment with the 5HT_{2A} agonist TCB-2 or antagonist MDL 11,939 before acquisition and retrieval of conditioned fear memory did not interfere with freezing expression of male mice, while TCB-2 administration posttraining enhanced freezing on CFC and TFC tests. As for the extinction learning, 5HT_{2A} activation is not essential, but facilitates the process (86). Altogether, these data suggest a role for the 5HT_{2A} receptor on plasticity mechanisms altering memory traces and behavioral responses, but that role is limited to already acquired memories and does not seem to influence the establishment of new associations.

Activation of postsynaptic 5HT_{1A} receptors, on the other hand, seems to decrease anxiety and stress responses. Systemic or intrahippocampal treatment with 5HT_{1A} agonist 8-OH-DPAT before CFC impairs fear memory retrieval, without significantly altering TFC memory retrieval. The impairments were not observed when treatment was administered after training. Additionally, WAY 100635, a 5HT_{1A} antagonist, was not able to produce memory alterations when administered alone, but prevented retrieval impairments when combined with 8-OH-DPAT. Opposed to the outcomes observed after 5HT_{2A} manipulation, 5HT_{1A} receptors seem to be relevant for memory acquisition, especially of HPP-dependent memories, like the CFC (87).

Serotonin Receptors' Role on Psychedelic Effects

The behavioral and mental alterations resulting from psychedelic administration are frequently associated to its agonism at 5HT_{2A} receptors. In humans, ketanserin, a 5HT_{2A/2C} antagonist, can be used to reduce subjective effects induced by LSD (100 or 200 µg) (88, 89). Pretreatment with ketanserin also prevents the psilocybin-induced (215 µg/kg) increase in positive affect and the decrease on recognition of negative facial expressions (90). For DMT (0.7 mg/kg, i.m.), pretreatment with cyproheptadine, another 5HT_{2A/2C} antagonist, did not interfere with subjective effects (91). On the other hand, pretreatment with pindolol, a 5HT_{1A/β}-adrenergic receptors antagonist, intensified DMT (0.1 mg/kg, i.v.) subjective reactions, suggesting an attenuation response of 5HT_{1A} receptors activation on DMT effects. The enhancement of subjective effects caused by pindolol could be a result of increased 5HT_{2A} signaling after 5HT_{1A} blockade (5).

Regarding AYA, pretreatment with ketanserin altered the neurophysiological oscillatory patterns induced by AYA (dose adjusted to contain 0.75 mg/kg of DMT) intake and blocked visual effects through blocking AYA-induced decrease in alpha oscillations (6).

Although the available literature mostly attributes the subjective effects of psychedelics to agonism at the 5HT_{2A} receptor, some evidence points out that not everything can be explained by it. In healthy volunteers, pretreatment with ketanserin did not prevent the reduction in attentional tracking ability caused by psilocybin (215 µg/kg), suggesting a role for 5HT_{1A} receptors (92). Combined administration of buspirone, 5HT_{1A} agonist, and psilocybin (170 µg/kg) reduced the acute subjective effects of psilocybin (93). In chronically stressed mice, treatment with ketanserin did not prevent the antidepressant effects of a single dose of psilocybin (1 mg/kg, i.p.) (94).

Preclinical Evidence for Ayahuasca' Effects on Fear and Anxiety-like Responses

Animal studies evaluating the effects of AYA administration are trying to decode how this substance can interfere with behavioral, functional and structural parameters of fear and anxiety-like responses, and how this could be linked to the possible therapeutic effects (Table 1).

A single oral administration of AYA (containing 9 mg/kg of DMT) to female rats decreased locomotion on the OFT and EPM, which could be an indication of anxiogenic effect, whilst it also decreased immobility on forced swim test (FST), an indication of antidepressant effect. The

**Table 1.** Fear and anxiety-like responses from preclinical studies

Training		Testing	Reconsolidation	Extinction
Fear memory tests				
AYA	–	Chronic pretreatment with AYA (120 mg/kg) increased freezing at CFC and TFC (99).	AYA treatment (60 mg/kg) pretreatment before or after reconsolidation session decreases fear expression on CFC test (12).	Single AYA (0.3 mg/kg of DMT) dose reduces freezing during CFC extinction training, but not test. However, two treatment paired extinction sessions decrease freezing during test (13). Single AYA dose (60 mg/kg) before retrieval, facilitates CFC extinction learning one day after (12).
DMT	Acute treatment with DMT (10 mg/kg) increased freezing during TFC (96). Chronic treatment with DMT (1 mg/kg) did not affect behavior during CFC and TFC training (100).	Acute treatment with DMT (10 mg/kg) before training did not alter fear response during TFC test (96). Chronic treatment with DMT (1 mg/kg) did not affect behavior during CFC and TFC test (100).	–	DMT acute (10 mg/kg) or chronic (1 mg/kg) treatment facilitated TFC, but not CFC, extinction (96, 100).
β -carbolines	Pre-training harmine (10 mg/kg) treatment did not alter aversive avoidance learning during PMDAT training (102).	Pre-training treatment with harmaline (1 mg/kg) impaired fear response at the step-down passive avoidance task (101). Pre-training harmine (10 mg/kg) treatment impaired fear response at CFC, but not TFC (102). Pre-training harmine (10 mg/kg) treatment impaired aversive-avoidance during PMDAT test (102).	–	–
Anxiety test				
AYA	Acute oral AYA dose (9 mg/kg of DMT) decreased locomotion on OFT and EPM (95). Acute oral AYA treatment (0.1, 0.3 of DMT) had no effect on time in the open arms and closed arm entries, but the higher AYA dose (1.0 mg/kg of DMT) increased closed arm entries and general exploratory behavior (13). Oral single dose of AYA (60 mg/kg) did not alter open arm and closed arm entries, and did not alter locomotion (12).			
DMT	One DMT dose (10 mg/kg, i.p.) reduced exploration in the OFT and open arms time and entries on EPM (96).			
β -carbolines	Acute harmine (5, 10, 15 mg/kg, i.p.) treatment did not alter behavioral expression on the OFT (98).			

AYA: Ayahuasca; CFC: Contextual fear conditioning; DMT: N,N-dimethyltryptamine; EPM: Elevated plus-maze; OFT: Open field test; PMDAT: Plus-maze discriminative avoidance task; TFC: Tone fear conditioning; –: Unavailable data.

treatment also induced an increase in *c-fos* expressing neurons in the DRN, posterior BLA and HPP (95). Male rats treated with one dose of DMT (10 mg/kg, i.p.) also presented reduced exploratory and increased anxiety-like behaviors, while three doses were able to induce antidepressant effects on the FST (96). Psilocybin, another 5HT_{2A} psychedelic agonist, also increases anxiety-like responses when administered 15 min prior to the OFT, but promotes anxiolytic effects when animals are tested 4 h after the administration (3 mg/kg, i.p.) (97).

Interestingly, acute treatment with harmine (10 or 15 mg/kg, i.p.) also induced the decrease in depressive-like responses on FST, without altering exploratory behaviors. Additionally, animals treated with the higher dose of harmine also presented increased hippocampal brain-derived neurotrophic factor (BDNF) expression (98).

Further comprehending how AYA can affect fear memory processing might help elucidate how this substance could be useful for treating disorders such as PTSD. Most preclinical studies on this theme focus on how

AYA treatment could alter an already established fear memory, which makes sense when considered from a translational point of view. Nevertheless, the results elicited by treatment with AYA and its constituent compounds prior to fear memory formation or during reconsolidation and extinction of already established memories seem to differently affect behavioral responses.

Rats chronically treated with AYA (120 mg/kg, oral) for 30 days and later submitted to CFC and TFC presented enhanced freezing behavior during the test. On TFC test, freezing was increased even before the CS presentation. Treatment with higher doses (240 and 480 mg/kg) did not alter behavioral expression (99). DMT (10 mg/kg, i.p.) also seems to influence freezing behavior when administered 1 h prior to TFC, increasing this behavior during training, but not during test (96). Chronic treatment with smaller doses of DMT (1 mg/kg, i.p.) before the conditioning protocol, on the other hand, does not increase freezing behavior on CFC and TFC tests (100).



β -carbolines, on the other hand, seem to present an amnesic effect when administered to animals prior to fear memory tasks. Harmaline (1 mg/kg, i.p.) injected to mice 5 min before a step-down passive avoidance task training prevented increased latency to step down 24 h later during the retention test (101). Harmine administered (10 mg/kg, i.p.) to rats 1 h before CFC and TFC conditioning decreased freezing behavior when animals were tested for CFC 24 h later but did not affect freezing on the TFC test 48 h later. Rats submitted to a plus-maze discriminative avoidance task (PMDAT) also were treated with harmine (5, 10, 15 mg/kg, i.p.) before the training. In this task, a regular elevated plus maze is used, but one of the closed arms will be equipped with visual and sound aversive stimuli. Every time the animal enters the aversive arm during training, the stimuli is continuously presented until the animal leaves the arm. Although during training all animals learned to avoid the aversive arm, indicating memory acquisition, 24 h later all harmine-treated groups were not significantly avoiding the aversive arm when compared with the other nonaversive arms (102).

Rats trained in a CFC protocol that received a single dose of ayahuasca (60 mg/kg) 20 min before or 3 h after a re-exposure session to the conditioned context present less freezing behavior when tested in the same context one day later. This decrease is not observed during the re-exposure session itself nor during the test when the animals are treated without being re-exposed to conditioned context previously to testing. Interestingly, the same results are reproduced even for remote memories, when the animals are tested 22 days after the re-exposure. These results suggest that ayahuasca could be acting on memory reconsolidation, reshaping the fear response as a consequence of the memory trace becoming more labile (12).

Regarding extinction protocols, the results are conflicting. The treatment with a single dose of DMT (10 mg/kg, i.p.) 1 h prior extinction training on TFC, as well as chronic treatment with smaller DMT doses (1 mg/kg, i.p.), seem to facilitate fear extinction (96, 100). However, in the CFC protocol, even multiple treatment-paired extinction sessions were not able to extinguish the fear response (96). On mouse submitted to TFC, psilocybin administration (2.5 mg/kg, i.p.) prior to extinction training decreased fear expression during training and during extinction tests 1 and 6 days after training (103).

AYA (adjusted to contain 0.3 mg/kg of DMT) administration to rats 1 h before a CFC extinction session decreases freezing behavior during the sessions, but the reduction is not sustained one day later on the extinction test. However, when the animal is submitted to two treatment-paired extinction sessions, the extinction memory is recalled when tested one day later (13). When the AYA (60 mg/kg) treatment was administered 20 min before or 3 h after a retrieval session, one day prior to extinction training, a single dose was sufficient to facilitate the acquisition of extinction memory (12). Chronic AYA treatment (120 mg/kg, oral) before CFC altered freezing expression, but did not affect extinction learning (99).

Even after extinction, re-exposing animals to the US can promote the reinstatement of the fear response. Treatment with AYA (60 mg/kg) 20 min before or 3 h after a retrieval session can prevent reinstatement after the acquisition of the extinction memory (12). However, when the treatment (adjusted to contain 0.3 mg/kg of DMT) is carried out during the extinction session, although the extinction memory is acquired, the reinstatement is not prevented (13).

The differences between the results observed for treatment with isolated compounds of AYA suggest the β -carbolines could be more effective targeting HPP-dependent memories, as is the case of CFC, step-down passive avoidance and PMDAT tasks. These amnesic effects can be an indication that β -carbolines are promoting increased neurogenesis, once increasing HPP neurogenesis on HPP-dependent tasks can promote forgetting (104). However, all available data test these substances on memory acquisition and early consolidation, while data regarding its effects on already established memory traces are still lacking (101, 102).

DMT, on the other hand, does not affect memory acquisition and early consolidation, although its administration before TFC enhances freezing response during the training. However, during extinction protocols for TFC, treating the animal with a single dose 1 h before the extinction session or a chronic treatment with smaller DMT doses can facilitate fear ex-

tingtion, but the same result does not occur on CFC trained animals (96, 100). These results suggest that, although DMT can interfere with fear processing, it is not effective for targeting HPP-dependent memories.

When AYA itself is being tested, the extinction and reconsolidation efficacy was linked to duration and frequency of exposure to the conditioned context. Extinction retention was dependent on animals being re-exposed to the conditioned context at least two times (12, 13). The current most widely accepted view on consolidation of recent into long-term memories posits that during this process the memory trace will increasingly rely more on cortical than on HPP activation (105). However, prolonged re-exposure to the conditioning context can lead to HPP activation, which then can make the already established memory once again susceptible to neurogenesis induced forgetting (104, 106). These data are reminiscent of exposure therapy protocols currently being employed to treat PTSD (31, 107). The effect of AYA on TFC reconsolidation and/or extinction protocols still needs to be tested.

Although these studies suggest that AYA and its components modulate fear memory processing, the conditioning protocols tested responses induced by nonpathological fear memories, since no protocol induced generalized fear behavior and most treatments did not increase anxiety-like responses when tested using the EPM (12, 13). The question remains whether the outcomes would be different when tested for pathological-like memories.

Trauma focused therapeutic interventions are currently widely employed and advised for treatment of PTSD (108). These interventions are based on the previously discussed premise that memory recall can facilitate the alteration of emotional and behavioral responses associated to the memory trace. However, even though data supporting trauma-focused therapies are the most robust for all currently employed therapeutic strategies, they are not always effective and, in many cases, the improvement is not sufficient to abolish PTSD diagnosis (109). Additionally, there is also reported variability in pharmacological treatment efficacy when comparing different traumatic events. For example, cannabidiol (300 mg) is effective in reducing anxiety and cognitive impairment triggered by traumatic memory recall only for nonsexual trauma (110).

Among other things, this variability can be a consequence of different symptomatology. The fifth edition of the Diagnostic and Statistical Manual for Mental Disorders (DSM-5) recognized a dissociative PTSD subtype, characterized by the presence of depersonalization and derealization symptoms (111). Compared with nondissociative PTSD, this subtype seems to be linked to increased cortical inhibition of limbic structures (112). In patients with borderline personality disorder, higher prevalence of dissociative experiences was a predictor for impaired acquisition and extinction of an AMY-dependent classic conditioning task (113).

Although animal models can be useful to understand different interventions outcomes on specific circuits, they lack precision to evaluate specific symptoms. Broadening the understanding of how PTSD can alter patients' brain functioning is essential to the development of better models.

Evidence for Ayahuasca' Effects on Fear and Anxiety Responses in Humans

Neuroimaging techniques used to investigate how AYA intake alters neural substrates suggest that it modulates structures and networks relevant to emotional processing.

In one study, healthy male subjects were randomized to receive AYA (adjusted to contain 1 mg/kg of DMT) or placebo and 100–110 min after intake participants were submitted to single photon emission tomography (SPECT) to assess how AYA altered regional cerebral blood flow (rCBF). Compared with placebo, AYA bilaterally increased rCBF on anterior insula and inferior frontal gyrus, increased rCBF on the right anterior cingulate and frontomedial cortex, and on the left AMY and parahippocampal gyrus (114). Another SPECT study, this time evaluating depressive patients, compared rCBF prior to and 8 h after AYA intake (2.2 mL/kg). The treatment increased rCBF on left nucleus accumbens, right insula and left subgenual anterior cingulate cortex (11).

Functional magnetic resonance imaging (fMRI) was used to assess AYA effects on the default mode network (DMN) in healthy volunteers.



Subjects were evaluated before and 40 min after AYA intake (2.2 mL/kg) when performing a verbal fluency task or during resting state. Results contrasted DMN signal during resting state and during task performing, and a decrease in signal was reported for the anterior and posterior cingulate cortices, mPFC, precuneus and inferior parietal lobules (115).

Hallucinogens effects evaluated through social cognition tasks can also be useful to better comprehend how these substances can alter emotional processing. Studies with healthy and clinical samples have been performed to evaluate how they can interfere with REFE.

A study with healthy volunteers compared how different LSD doses (100 or 200 μ g) could alter REFE performance when compared with placebo. Subjects were tested 5 h after intake of the lower dose and 7 h after intake of the higher one, and both doses decreased accuracy for recognition of fearful expressions (116). Another study by the same group used fMRI to compare how healthy individuals respond when presented to fearful or neutral expressions. Each subject received 100 μ g of LSD or placebo 2.5 h before the scan. Compared with placebo, LSD reduced neural response to fearful versus neutral faces on left AMY and right medial frontal gyrus. The AMY activation to fearful faces was also negatively correlated to reported subjective drug effects (117). Also, administration of psilocybin (215 μ g/kg) to healthy subjects decreased the recognition of negative facial expressions when compared with placebo (90).

Regarding AYA, healthy volunteers were submitted to fMRI before and after drug intake (25–35 mL, 0.333 ± 0.056 mg/kg DMT), and asked to perform a task with implicit emotional stimuli (neutral, disgusted or fearful facial expressions). Before AYA intake, reaction time was longer when aversive stimuli were presented, but during the AYA effects, the reaction time was no longer different for neutral and aversive stimuli. Together with the behavioral alterations, AMY responsiveness to aversive stimuli was attenuated by AYA, while the anterior insula and the dorsolateral PFC responsiveness increased (118). Similarly, increases in reaction time in a REFE task were observed in healthy volunteers after a single AYA dose (1 mL/kg; ± 0.72 mg/mL DMT) (119). On the other hand, a previous study evaluating the effects of a single dose of ayahuasca (1 mL/kg; ± 1.58 mg/mL DMT) in healthy volunteers did not identify behavioral differences on REFE performance when compared with the placebo group (120). However, these studies did not assess parameters regarding neural activity, which could be altered even in the absence of behavioral outcomes.

Although the clinical evidence assessing the effects of AYA on fear and anxiety disorders is still scarce, a few observational and experimental studies with healthy subjects explored its effects on trauma, memory, anxiety and phobia measurements.

Long-term members of ayahuasca churches in Brazil (over 15 years), when compared with actively practicing religious individuals from catholic and protestant churches, showed lower scores on phobic anxiety availed through the Symptom Checklist 90 – Revised (SCL-30-R), a self-report inventory to assess psychopathologies (121). An observational, naturalistic study conducted with healthy participants taking part on a AYA traditional indigenous retreat in Peru used the Sentence Completion for Events from the Past Test (SCEPT) to evaluate how the hallucinogenic experience could alter their perception of autobiographical memories, and a significant reduction on scores for negative valence memories was observed when comparing the baseline with postretreatment at the 6 months follow-up. However, it is important to point out that these participants did not present a high level of traumatic childhood experiences, as assessed through the Childhood Trauma Questionnaire scores collected on baseline (14).

An experimental double-blinded study with experienced members of an AYA church assessed panic and anxiety outcomes during the substance peak effects (1 h after ingestion). AYA (3 mL) and placebo scores were compared with baseline, and only AYA was effective in reducing panic-related signs assessed through the Anxiety Sensitivity Index. Anxiety was assessed using the State-Trait Anxiety Inventory (STAI), but the placebo and AYA scores did not differ from baseline (122).

Another study investigated the subjective effects of AYA (1 mL/kg; ± 0.72 mg/mL DMT) combined with placebo or cannabidiol (600 mg) on healthy subjects using the Visual Analogue Mood Scale (VAMS). During

AYA effects participants reported a decrease in anxiety, independently from the pretreatment group (119).

Regarding clinical populations, a recent case series reported the use of AYA to treat PTSD in war veterans taking part in a retreat. The Post-traumatic Stress Checklist (PCL-5) was used to assess PTSD symptoms and to evaluate clinical changes through the protocol. Most participants (7 out of 8) lowered PCL-5 scores after the intervention, and 5 of them still had lower scores 3 months after the intervention when compared with baseline. More than half of the participants reported intensely experiencing intrusive memories of the traumatic event. After the intervention, the largest improvements were observed in Cluster E symptoms, concerning sleep disturbances, hypervigilance, and concentration difficulties, and although some participants reported a reduction on intrusive memories, it was not statistically significant (15).

AYA was also tested in a randomized, placebo-controlled trial with subjects diagnosed with social anxiety disorder. Participants received a single dose of ayahuasca (2 mL/kg, ± 0.68 mg/mL DMT) or placebo and, after the acute effects (300 min after intake), they were submitted to the SPST. During the protocol, anxiety and self-perception of performance were assessed using the VAMS, the Beck Anxiety Inventory and the State Version of the Self-statements During Public Speaking Scale. No significant differences were found between groups on the anxiety measures, but the AYA group showed improved perception of performance when compared with placebo (7).

The observational and experimental data available imply that ayahuasca might be a potential treatment for anxiety and stress disorders; however, there is a lack of studies with clinical populations conducted on controlled settings. Since AYA is an element of traditional cultures, there is an inherent challenge on variability control of AYA studies. It cannot be manufactured with commercial purposes, and the absence of standardized procedures lead to brew batches with highly diverse alkaloid composition and concentration, which reflects on the dosage variability present in naturalistic and experimental settings.

Synthetic formulations are already being tested as a possible alternative to try improving this variability, and to try to deal with ethical problems attached to the use of traditional formulations (123).

Ayahuasca Effects on Fear and Anxiety Responses Through 5HT Signaling

The currently available data suggest that AYA and its constituent substances, that is, DMT and β -carbolines, can modulate fear and anxiety responses. However, molecular and functional data supporting the behavioral and clinical observations are still scarce.

Neuronal and synaptic plasticity mechanisms are a fundamental aspect supporting behavioral flexibility. Increasing effort has been made into elucidating psychedelic induced plasticity, and it is possible that they hold the answer for the fast-acting therapeutic properties these substances apparently have.

Similarly to other psychedelic substances, DMT can promote increased neurogenesis and synaptogenesis on cortical neurons. This effect is possibly mediated by BDNF interaction with TrkB receptors and subsequent activation of mTOR intracellular signaling pathways (18). Mice chronically treated with harmine (20 mg/kg, i.p. for 10 days) also present increased BDNF expression on the PFC (124) (Figure 1A). In humans, healthy and depressive participants receiving a single AYA dose (1 mL/kg) expressed increased BDNF serum levels 48 h after intake when compared with placebo groups (125).

On cortical neurons, DMT plasticity increasing properties are dependent on 5HT_{2A} receptors activation (18). However, injection of a 5HT_{2A} antagonist into the IL did not prevent AYA facilitation of extinction learning and recall on rats previously submitted to CFC, even though it increased freezing levels during extinction sessions (13). The increased freezing expression might be due to a decrease in the inhibitory control over central AMY projections, since the IL PNs innervate the ITC which then inhibits central AMY (126) and the PNs activation might be regulated by the 5HT_{2A} receptor.

Increased plasticity at the IL is necessary for extinction memory retention (127); however, 5HT_{2A} antagonism did not impair extinction




Figure 1. Plasticity-promoting mechanisms triggered by DMT and BC. (A) DMT and BC-induced increase in cortical plasticity are linked to enhanced BDNF levels, although this might result from activation of different receptors. (B) Increased hippocampal plasticity and neurogenesis induced by DMT and BC rely on different molecular pathways. 5HT2A: serotonergic receptor 2A subtype; BC: β -carboline; BDNF: brain-derived neurotrophic factor; DMT: N,N-dimethyltryptamine; SIGMA1: sigma receptor subtype 1.

learning. A possible explanation is the fact that extinction learning relies on BDNF increase on HPP inputs to the IL (128), so even though 5HT2A antagonism could prevent DMT induced plasticity at the IL, the extinction memory was not affected.

On the other hand, the same protocol testing a 5HT1A antagonist prevented AYA effects on extinction retention or recall, although it did not alter the decrease in fear expression during extinction learning (13). IL projections to BLA are necessary for extinction retention (129), and these data suggest that this effect might be mediated by 5HT1A activity. The IL projects to BLA PNs and INs, and during fear extinction synaptic efficacy of PNs innervation is reduced through a process that might resembles a long-term depression (126). Since 5HT1A receptors are relevant to modulate input-generated excitability on cortical PNs, it is possible that they are involved in the synaptic efficacy decrease. AYA and DMT acute treatments in rodents can lead to an increase in anxiety-like responses on EPM and FST, despite also inducing an antidepressant effect on the FST (95, 96). This increase in conflict anxiety responses could be a consequence of 5HT2A receptor activation by these compounds. Interestingly, different from what is observed after AYA and DMT administration, β -carbolines do not induce an increase in anxiety-like response despite their mild affinity for 5HT2A receptors (98).

Harmine chronic administration (20 mg/kg, i.p. for 10 days) can increase HPP neurogenesis in mice (124), which could also explain the behavioral outcomes of β -carbolines administration on HPP-dependent tasks (Figure 1B). Oppositely to the effects of 5HT2A activation on cortical neurons, on the HPP this receptor is not linked to plasticity increase. Rats treated with DOI, another psychedelic compound, present decreased HPP BDNF mRNA expression, whilst still having increased BDNF levels on cortical areas. This modulation was completely blocked by a 5HT2A antagonist administration. Interestingly, immobilization stress also results in a decrease in BDNF mRNAs on the HPP through 5HT2A activation (130).

Hence, 5HT2A activation on the HPP possibly does not contribute to the antidepressant and might be responsible for the anxiogenic DMT ef-

fects. Nevertheless, DMT treatment can induce neurogenesis on HPP, but the mechanism seems to result from sigma-1 receptors activation instead (131) (Figure 1B).

It is possible that the β -carbolines effect on depressive-like behaviors as well as in HPP-dependent memories could rely on its antagonism of monoamine oxidase enzymes, that could increase circulating levels of 5HT. Additionally, since they do not present affinity for 5HT1A receptors, they would not activate the raphe nuclei autoreceptors, preventing the decrease in 5HT release observed after acute administration of 5HT1A agonists (79, 132).

Possibly, β -carbolines administration could somehow predominantly activate specific raphe nuclei pathways, since the behavioral responses observed after its administration resemble the median raphe forebrain bundle tract mediated responses. This pathway directly controls HPP activity, and increased activity in this circuit is linked to antidepressant behavioral responses (133). Also, this pathway stimulation can desynchronize HPP theta oscillations, which are relevant for associative memory processing (134). This could explain why β -carbolines treatment seems to be more effective on interfering with HPP-dependent memory processing. The anxiety-like responses evoked by acute treatment with DMT suggests this substance might be acting on substrates innervated by the DRD/DRC projections and would explain the lack of effects of DMT treatment on CFC extinction, since this task is HPP-dependent. On the other hand, β -carbolines preferential effect on DRI/MnR pathway could explain the lack of treatment-induced anxiety-like behaviors, despite their mild 5HT2A affinity, besides the antidepressant properties and amnesic effects on HPP-dependent memories processing.

Future Perspectives

Although AYA has been employed in therapeutic and religious contexts for centuries, there is still a lot to be dissected on its biological and psychological effects. The complex nature of this brew, that combines different alkaloids, adds another layer of intricacy to an already challenging task.



In currently available literature, DMT is frequently mentioned as the main psychoactive constituent of AYA, however many studies discussed throughout this review highlight relevant differences on isolated DMT effects when compared with AYA or β -carbolines. Although β -carbolines lack the mind-altering properties of AYA and DMT, they seem to have therapeutic properties as well. More studies investigating the molecular pathways supporting antidepressant and memory effects elicited by them could improve comprehension on AYA, as well as indicate contexts where isolated β -carbolines could be employed as treatment. Hereof, differences on HPP plasticity and neurogenesis molecular pathways activated by DMT and β -carbolines could clarify the distinct behavioral outcomes promoted by these substances.

Regarding human studies, there is still a long way to go. The observational and experimental studies investigating healthy populations support the relevance of further investigations; however, clinical studies are still lacking, especially in controlled settings. The unknown risks that psychedelic intake can represent to specific clinical populations together with the prejudice accumulated from years of criminalization are some of the challenges faced by the researchers. On top of that, the increasing hype around psychedelic therapeutic effects can result in a positive bias. Controlling this bias is also a difficult task, since blinding is still a challenge for the field.

Final Remarks

In an attempt to associate the emerging data on hallucinogens therapeutic properties for treatment of mental disorders and the classical Deakin/Graeff theory linking fear and anxiety responses to 5HT signaling, Carhart-Harris and Nutt (2017) propose that hallucinogen-induced 5HT_{2A} agonism, and the subsequent activation-induced plasticity, mediate active coping in a similar idea to the DRD/DRC projections. In the same review, they also propose that passive coping would be the mechanism supporting conventional antidepressants efficacy, such as SSRIs, and would be mediated by 5HT_{1A} activity, similarly to the DRI/MnR pathway (135).

Through that perspective, AYA therapeutic properties could be a combination of active and passive coping mechanisms. The β -Carbolines apparent capacity to modulate HPP activity, in what they call passive coping, could be a relevant factor behind AYA effects on CFC extinction that could not be reproduced by DMT treatment. DMT, on the other hand, seem to behave similarly to what is proposed for other classic hallucinogens, favoring active coping strategies and mechanisms.

Author Contributions

LTLG, MSc prepared the original draft. RGDS, PhD intellectual conceptualization, review and editing the manuscript. JECH, MD, PhD intellectual conceptualization, review and editing the manuscript.

Funding Sources

LTLG received funding from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil). JECH is recipient of CNPq 1A productivity fellowship.

Author Disclosures

The authors declare no conflicts of interest. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The manuscript has been read and approved by all authors.

References

- Domínguez-Clavé E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, et al. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. *Brain Res Bull*. 2016;126:89–101. DOI: [10.1016/j.brainresbull.2016.03.002](https://doi.org/10.1016/j.brainresbull.2016.03.002). PMID: 26976063
- Kim H, Sablin SO, Ramsay RR. Inhibition of monoamine oxidase A by β -carbolines derivatives. *Arch Biochem Biophys*. 1997;337(1):137–42. DOI: [10.1006/abbi.1996.9771](https://doi.org/10.1006/abbi.1996.9771). PMID: 8990278
- Glennon RA, Dukat M, Grella B, Hong SS, Costantino L, Teitler M, et al. Binding of β -carbolines and related agents at serotonin (5-HT₂ and 5-HT_{1A}), dopamine (D₂) and benzodiazepine receptors. *Drug Alcohol Depend*. 2000;60(2):121–32. DOI: [10.1016/S0376-8716\(99\)00148-9](https://doi.org/10.1016/S0376-8716(99)00148-9). PMID: 10940539
- Vollenweider FX, Smallridge JW. Classic psychedelic drugs: update on biological mechanisms. *Pharmacopsychiatry*. 2022;55(03):121–38. DOI: [10.1055/a-1721-2914](https://doi.org/10.1055/a-1721-2914). PMID: 35079988; PMCID: [PMC9110100](https://pubmed.ncbi.nlm.nih.gov/PMC9110100/)
- Strassman RJ. Human psychopharmacology of N, N-dimethyltryptamine. *Behav Brain Res*. 1995;73(1):121–4. DOI: [10.1016/0166-4328\(96\)00081-2](https://doi.org/10.1016/0166-4328(96)00081-2). PMID: 8788488
- Valle M, Maqueda AE, Rabella M, Rodríguez-Pujadas A, Antonijoo RM, Romero S, et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. *Eur Neuropsychopharmacol*. 2016;26(7):1161–75. DOI: [10.1016/j.euroneuro.2016.03.012](https://doi.org/10.1016/j.euroneuro.2016.03.012). PMID: 27039035
- Dos Santos RG, Osório FDL, Rocha JM, Rossi GN, Bouso JC, Rodrigues LS, et al. Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial. *J Clin Psychopharmacol*. 2021;41(5):540–50. DOI: [10.1097/JCP.0000000000001428](https://doi.org/10.1097/JCP.0000000000001428). PMID: 34166299
- Osório FL, Sanches RF, Macedo LR, dos Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. *Braz J Psychiatry*. 2015;37:13–20. DOI: [10.1590/1516-4446-2014-1496](https://doi.org/10.1590/1516-4446-2014-1496). PMID: 25806551
- Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. *Psychol Med*. 2019;49(4):655–63. DOI: [10.1017/S0033291718001356](https://doi.org/10.1017/S0033291718001356). PMID: 29903051; PMCID: [PMC6378413](https://pubmed.ncbi.nlm.nih.gov/PMC6378413/)
- Rodrigues LS, Reis JAS, Rossi GN, Guerra LTL, Maekawa RM, De Lima Osório F, et al. Effects of a single dose of ayahuasca in college students with harmful alcohol use: a single-blind, feasibility, proof-of-concept trial. *J Clin Psychopharmacol*. 2024;44(4):402–6. DOI: [10.1097/JCP.0000000000001872](https://doi.org/10.1097/JCP.0000000000001872). PMID: 38820373
- Sanches RF, de Lima Osório F, dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. *J Clin Psychopharmacol*. 2016;36(1):77–81. DOI: [10.1097/JCP.0000000000000436](https://doi.org/10.1097/JCP.0000000000000436). PMID: 26650973
- Daneluz DM, Sohn JMB, Silveira GO, Yonamine M, Stern CA. Evidence on the impairing effects of Ayahuasca on fear memory reconsolidation. *Psychopharmacology (Berl)*. 2022;239(10):3325–36. DOI: [10.1007/s00213-022-06217-2](https://doi.org/10.1007/s00213-022-06217-2). PMID: 36069952
- Werle I, Nascimento LMM, dos Santos ALA, Soares LA, dos Santos RG, Hallak JEC, et al. Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT_{2A} and 5-HT_{1A} receptors. *Br J Pharmacol*. 2024;181(11):1671–89. DOI: [10.1111/bph.16315](https://doi.org/10.1111/bph.16315). PMID: 38320596
- Ruffell SGD, Netzband N, Tsang W, Davies M, Inserra A, Butler M, et al. Ceremonial ayahuasca in amazonian retreats—mental health and epigenetic outcomes from a six-month naturalistic study. *Front Psychiatry*. 2021;12:687615. DOI: [10.3389/fpsy.2021.687615](https://doi.org/10.3389/fpsy.2021.687615). PMID: 34177670; PMCID: [PMC8221532](https://pubmed.ncbi.nlm.nih.gov/PMC8221532/)
- Weiss B, Dinh-Williams LAL, Beller N, Raugh IM, Strauss GP, Campbell WK. Ayahuasca in the treatment of posttraumatic stress disorder: mixed-methods case series evaluation in military combat veterans. *Psychol Trauma*. 2023. DOI: [10.1037/tra0001625](https://doi.org/10.1037/tra0001625). PMID: 38059941
- Brierley DI, Davidson C. Harmaline augments electrically evoked dopamine efflux in the nucleus accumbens shell. *J Psychopharmacol*. 2013;27(1):98–108. DOI: [10.1177/0269881112463125](https://doi.org/10.1177/0269881112463125). PMID: 23076833
- Dos Santos RG, Rocha JM, Rossi GN, Osório FL, Ona G, Bouso JC, et al. Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials. *Hum Psychopharmacol*. 2022;37(4):e2834. DOI: [10.1002/hup.2834](https://doi.org/10.1002/hup.2834). PMID: 35107855
- Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. *Cell Rep*. 2018;23(11):3170–82. DOI: [10.1016/j.celrep.2018.05.022](https://doi.org/10.1016/j.celrep.2018.05.022). PMID: 29898390; PMCID: [PMC6082376](https://pubmed.ncbi.nlm.nih.gov/PMC6082376/)
- Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous Sigma-1 receptor regulator. *Science*. 2009;323(5916):934–7. DOI: [10.1126/science.1166127](https://doi.org/10.1126/science.1166127). PMID: 19213917; PMCID: [PMC2947205](https://pubmed.ncbi.nlm.nih.gov/PMC2947205/)
- Inserra A. Hypothesis: the psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process. *Front Pharmacol*. 2018;9:330. DOI: [10.3389/fphar.2018.00330](https://doi.org/10.3389/fphar.2018.00330). PMID: 29674970; PMCID: [PMC5895707](https://pubmed.ncbi.nlm.nih.gov/PMC5895707/)
- dos Santos RG, Valle M, Bouso JC, Nomdedéu JF, Rodríguez-Espinosa J, McIlhenry EH, et al. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. *J Clin Psychopharmacol*. 2011;31(6):717–26. DOI: [10.1097/JCP.0b013e31823607f6](https://doi.org/10.1097/JCP.0b013e31823607f6). PMID: 22005052



22. Kim JJ, Jung MW. Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review. *Neurosci Biobehav Rev.* 2006;30(2):188–202. DOI: [10.1016/j.neubiorev.2005.06.005](https://doi.org/10.1016/j.neubiorev.2005.06.005). PMID: 16120461; PMCID: [PMC4342048](https://pubmed.ncbi.nlm.nih.gov/PMC4342048/)
23. Grillon C. Models and mechanisms of anxiety: evidence from startle studies. *Psychopharmacology (Berl.)*. 2008;199(3):421–37. DOI: [10.1007/s00213-007-1019-1](https://doi.org/10.1007/s00213-007-1019-1). PMID: 18058089; PMCID: [PMC2711770](https://pubmed.ncbi.nlm.nih.gov/PMC2711770/)
24. Zangrossi H, Del Ben CM, Graeff FG, Guimarães FS. Serotonin in panic and anxiety disorders. *Handbook of Behavioral Neuroscience*. London, United Kingdom: Elsevier; 2020. p. 611–33.
25. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. *J Neurosci Methods.* 1985;14(3):149–67. DOI: [10.1016/0165-0270\(85\)90031-7](https://doi.org/10.1016/0165-0270(85)90031-7). PMID: 2864480
26. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. *Eur J Pharmacol.* 2003;463(1):3–33. DOI: [10.1016/s0014-2999\(03\)01272-x](https://doi.org/10.1016/s0014-2999(03)01272-x). PMID: 12600700
27. Blanchard RJ, Fukunaga KK, Blanchard DC. Environmental control of defensive reactions to footshock. *Bull Psychon Soc.* 1976;8(2):129–30.
28. Fanselow MS. Conditional and unconditional components of post-shock freezing. *Pavlov J Biol Sci.* 1980;15(4):177–82. DOI: [10.1007/BF03001163](https://doi.org/10.1007/BF03001163). PMID: 7208128
29. Curzon P, Rustay NR, Browman KE. Cued and contextual fear conditioning for rodents. *Methods of Behavior Analysis in Neuroscience*. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis; 2009.
30. Kida S. Interaction between reconsolidation and extinction of fear memory. *Brain Res Bull.* 2023;195:141–4. DOI: [10.1016/j.brainresbull.2023.02.009](https://doi.org/10.1016/j.brainresbull.2023.02.009). PMID: 36801360
31. Kida S. Reconsolidation/destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD. *Psychopharmacology (Berl.)*. 2019;236(1):49–57. DOI: [10.1007/s00213-018-5086-2](https://doi.org/10.1007/s00213-018-5086-2). PMID: 30374892; PMCID: [PMC6373183](https://pubmed.ncbi.nlm.nih.gov/PMC6373183/)
32. Ekman P. An argument for basic emotions. *Cogn Emot.* 1992;6(3–4):169–200.
33. Bottinelli F, Delvecchio G, Moltrasio C, Ferro A, Diwadkar VA, Brambilla P. Facial emotion recognition in panic disorder: a mini-review of behavioural studies. *J Affect Disord.* 2021;282:173–8. DOI: [10.1016/j.jad.2020.12.064](https://doi.org/10.1016/j.jad.2020.12.064). PMID: 33418364
34. Reis JAS, Rossi GN, Osório FL, Bouso JC, Hallak JEC, Dos Santos RG. Interventions for deficits in recognition of emotions in facial expressions in major depressive disorder: An updated systematic review of clinical trials. *Neurosci Biobehav Rev.* 2023;153:105367. DOI: [10.1016/j.neubiorev.2023.105367](https://doi.org/10.1016/j.neubiorev.2023.105367). PMID: 37619644
35. Williams CL, Milanak ME, Judah MR, Berenbaum H. The association between PTSD and facial affect recognition. *Psychiatry Res.* 2018;265:298–302. DOI: [10.1016/j.psychres.2018.04.055](https://doi.org/10.1016/j.psychres.2018.04.055). PMID: 29778050
36. McNair DM, Frankenthaler LM, Czerlinsky T, White TW, Sasson S, Fisher S. Simulated public speaking as a model of clinical anxiety. *Psychopharmacology (Berl.)*. 1982;77(1):7–10. DOI: [10.1007/BF00436092](https://doi.org/10.1007/BF00436092). PMID: 6126900
37. Jacobs DS, Moghaddam B. Medial prefrontal cortex encoding of stress and anxiety. *Int Rev Neurobiol.* 2021;158:29–55. DOI: [10.1016/bs.irn.2020.11.014](https://doi.org/10.1016/bs.irn.2020.11.014). PMID: 33785149
38. Laubach M, Amarante LM, Swanson K, White SR. What, if anything, is rodent prefrontal cortex? *eNeuro.* 2018;5(5):ENEURO.0315-18.2018. DOI: [10.1523/ENEURO.0315-18.2018](https://doi.org/10.1523/ENEURO.0315-18.2018). PMID: 30406193; PMCID: [PMC6220587](https://pubmed.ncbi.nlm.nih.gov/PMC6220587/)
39. Vertes RP. Differential projections of the infralimbic and prelimbic cortex in the rat. *Synapse.* 2004;51(1):32–58. DOI: [10.1002/syn.10279](https://doi.org/10.1002/syn.10279). PMID: 14579424
40. Stevenson CW. Role of amygdala–prefrontal cortex circuitry in regulating the expression of contextual fear memory. *Neurobiol Learn Mem.* 2011;96(2):315–23. DOI: [10.1016/j.nlm.2011.06.005](https://doi.org/10.1016/j.nlm.2011.06.005). PMID: 21689772
41. Courtin J, Chaudun F, Rozeske RR, Karalis N, Gonzalez-Campo C, Wurtz H, et al. Prefrontal parvalbumin interneurons shape neuronal activity to drive fear expression. *Nature.* 2014;505(7481):92–6. DOI: [10.1038/nature12755](https://doi.org/10.1038/nature12755). PMID: 24256726
42. Quirk GJ, Russo GK, Barron JL, Lebron K. The role of ventromedial prefrontal cortex in the recovery of extinguished fear. *J Neurosci.* 2000;20(16):6225–31. DOI: [10.1523/JNEUROSCI.20-16-06225.2000](https://doi.org/10.1523/JNEUROSCI.20-16-06225.2000). PMID: 10934272; PMCID: [PMC6772571](https://pubmed.ncbi.nlm.nih.gov/PMC6772571/)
43. Do-Monte FH, Manzano-Nieves G, Quiñones-Laracunte K, Ramos-Medina L, Quirk GJ. Revisiting the role of infralimbic cortex in fear extinction with optogenetics. *J Neurosci.* 2015;35(8):3607–15. DOI: [10.1523/JNEUROSCI.3137-14.2015](https://doi.org/10.1523/JNEUROSCI.3137-14.2015). PMID: 25716859; PMCID: [PMC4339362](https://pubmed.ncbi.nlm.nih.gov/PMC4339362/)
44. Bishop SJ. Trait anxiety and impoverished prefrontal control of attention. *Nat Neurosci.* 2009;12(1):92–8. DOI: [10.1038/nn.2242](https://doi.org/10.1038/nn.2242). PMID: 19079249
45. Park J, Wood J, Bondi C, Del Arco A, Moghaddam B. Anxiety evokes hypofrontality and disrupts rule-relevant encoding by dorsomedial prefrontal cortex neurons. *J Neurosci.* 2016;36(11):3322–35. DOI: [10.1523/JNEUROSCI.4250-15.2016](https://doi.org/10.1523/JNEUROSCI.4250-15.2016). PMID: 26985040; PMCID: [PMC4792942](https://pubmed.ncbi.nlm.nih.gov/PMC4792942/)
46. Park J, Moghaddam B. Impact of anxiety on prefrontal cortex encoding of cognitive flexibility. *Neuroscience.* 2017;345:193–202. DOI: [10.1016/j.neuroscience.2016.06.013](https://doi.org/10.1016/j.neuroscience.2016.06.013). PMID: 27316551; PMCID: [PMC5159328](https://pubmed.ncbi.nlm.nih.gov/PMC5159328/)
47. Likhtik E, Stujenske JM, Topiwala MA, Harris AZ, Gordon JA. Prefrontal entrainment of amygdala activity signals safety in learned fear and innate anxiety. *Nat Neurosci.* 2014;17(1):106–13. DOI: [10.1038/nn.3582](https://doi.org/10.1038/nn.3582). PMID: 24241397; PMCID: [PMC4035371](https://pubmed.ncbi.nlm.nih.gov/PMC4035371/)
48. Via E, Fullana MA, Goldberg X, Tinoco-González D, Martínez-Zalacaín I, Soriano-Mas C, et al. Ventromedial prefrontal cortex activity and pathological worry in generalised anxiety disorder. *Br J Psychiatry.* 2018;213(1):437–43. DOI: [10.1192/bjp.2018.65](https://doi.org/10.1192/bjp.2018.65). PMID: 29739481
49. Chen Y, Hu N, Yang J, Gao T. Prefrontal cortical circuits in anxiety and fear: an overview. *Front Med.* 2022;16(4):518–39. DOI: [10.1007/s11684-022-0941-2](https://doi.org/10.1007/s11684-022-0941-2). PMID: 35943704
50. Janak PH, Tye KM. From circuits to behaviour in the amygdala. *Nature.* 2015;517(7534):284–92. DOI: [10.1038/nature14188](https://doi.org/10.1038/nature14188). PMID: 25592533; PMCID: [PMC4565157](https://pubmed.ncbi.nlm.nih.gov/PMC4565157/)
51. LeDoux J. The amygdala. *Curr Biol.* 2007;17(20):R868–74. DOI: [10.1016/j.cub.2007.08.005](https://doi.org/10.1016/j.cub.2007.08.005). PMID: 17956742
52. Goossens KA, Maren S. NMDA receptors are essential for the acquisition, but not expression, of conditional fear and associative spike firing in the lateral amygdala. *Eur J Neurosci.* 2004;20(2):537–48. DOI: [10.1111/j.1460-9568.2004.03513.x](https://doi.org/10.1111/j.1460-9568.2004.03513.x). PMID: 15233763
53. Viviani D, Charlet A, van den Burg E, Robinet C, Hurni N, Abatis M, et al. Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. *Science.* 2011;333(6038):104–7. DOI: [10.1126/science.1201043](https://doi.org/10.1126/science.1201043). PMID: 21719680
54. Jüngling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD, et al. Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. *Neuron.* 2008;59(2):298–310. DOI: [10.1016/j.neuron.2008.07.002](https://doi.org/10.1016/j.neuron.2008.07.002). PMID: 18667157; PMCID: [PMC2610688](https://pubmed.ncbi.nlm.nih.gov/PMC2610688/)
55. Goossens KA, Maren S. Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. *Learn Mem.* 2001;8(3):148–55. DOI: [10.1101/lm.37601](https://doi.org/10.1101/lm.37601). PMID: 11390634; PMCID: [PMC311374](https://pubmed.ncbi.nlm.nih.gov/PMC311374/)
56. Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H, et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. *Nature.* 2011;471(7338):358–62. DOI: [10.1038/nature09820](https://doi.org/10.1038/nature09820). PMID: 21389985; PMCID: [PMC3154022](https://pubmed.ncbi.nlm.nih.gov/PMC3154022/)
57. Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. *Arch Gen Psychiatry.* 2009;66(12):1361–72. DOI: [10.1001/archgenpsychiatry.2009.104](https://doi.org/10.1001/archgenpsychiatry.2009.104). PMID: 19996041
58. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. *Neuropsychopharmacology.* 2010;35(1):169–91. DOI: [10.1038/npp.2009.83](https://doi.org/10.1038/npp.2009.83). PMID: 19625997; PMCID: [PMC3055419](https://pubmed.ncbi.nlm.nih.gov/PMC3055419/)
59. Moser MB, Moser EI. Functional differentiation in the hippocampus. *Hippocampus.* 1998;8(6):608–19. DOI: [10.1002/\(SICI\)1098-1063\(1998\)8:6<608::AID-HIPO3>3.0.CO;2-7](https://doi.org/10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7). PMID: 9882018
60. Kim JJ, Fanselow MS. Modality-specific retrograde amnesia of fear. *Science.* 1992;256(5057):675–7. DOI: [10.1126/science.1585183](https://doi.org/10.1126/science.1585183). PMID: 1585183
61. Terreros-Roncal J, Flor-García M, Moreno-Jiménez EP, Rodríguez-Moreno CB, Márquez-Valadez B, Gallardo-Caballero M, et al. Methods to study adult hippocampal neurogenesis in humans and across the phylogeny. *Hippocampus.* 2022;33(4):271. DOI: [10.1002/hipo.23474](https://doi.org/10.1002/hipo.23474). PMID: 36259116; PMCID: [PMC7614361](https://pubmed.ncbi.nlm.nih.gov/PMC7614361/)
62. Gandhi S, Gupta J, Tripathi PP. The curious case of human hippocampal neurogenesis. *ACS Chem Neurosci.* 2019;10(3):1131–2. DOI: [10.1021/acschemneuro.9b00063](https://doi.org/10.1021/acschemneuro.9b00063). PMID: 30724553
63. Tunc-Ozcan E, Peng CY, Zhu Y, Dunlop SR, Contractor A, Kessler JA. Activating newborn neurons suppresses depression and anxiety-like behaviors. *Nat Commun.* 2019;10(1):3768. DOI: [10.1038/s41467-019-11641-8](https://doi.org/10.1038/s41467-019-11641-8). PMID: 31434877; PMCID: [PMC6704083](https://pubmed.ncbi.nlm.nih.gov/PMC6704083/)
64. Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? *Neuron.* 2010;65(1):7–19. DOI: [10.1016/j.neuron.2009.11.031](https://doi.org/10.1016/j.neuron.2009.11.031). PMID: 20152109; PMCID: [PMC2822727](https://pubmed.ncbi.nlm.nih.gov/PMC2822727/)
65. Corcoran KA, Maren S. Hippocampal inactivation disrupts contextual retrieval of fear memory after extinction. *J Neurosci.* 2001;21(5):1720–6. DOI: [10.1523/JNEUROSCI.21-05-01720.2001](https://doi.org/10.1523/JNEUROSCI.21-05-01720.2001). PMID: 11222661; PMCID: [PMC6762930](https://pubmed.ncbi.nlm.nih.gov/PMC6762930/)
66. Pereira LM, de Castro CM, Guerra LTL, Queiroz TM, Marques JT, Pereira GS. Hippocampus and prefrontal cortex modulation of contextual fear memory is dissociated by inhibiting de novo transcription during late consolidation. *Mol Neurobiol.* 2019;56(8):5507–19. DOI: [10.1007/s12035-018-1463-4](https://doi.org/10.1007/s12035-018-1463-4). PMID: 30623374



67. Adhikari A, Topiwala MA, Gordon JA. Synchronized activity between the ventral hippocampus and the medial prefrontal cortex during anxiety. *Neuron*. 2010;65(2):257–69. DOI: [10.1016/j.neuron.2009.12.002](https://doi.org/10.1016/j.neuron.2009.12.002). PMID: 20152131; PMCID: [PMC2822726](https://pubmed.ncbi.nlm.nih.gov/PMC2822726/)
68. Kjelstrup KG, Tuvnes FA, Steffenach HA, Murison R, Moser EI, Moser MB. Reduced fear expression after lesions of the ventral hippocampus. *Proc Natl Acad Sci U S A*. 2002;99(16):10825–30. DOI: [10.1073/pnas.152112399](https://doi.org/10.1073/pnas.152112399). PMID: 12149439; PMCID: [PMC125057](https://pubmed.ncbi.nlm.nih.gov/PMC125057/)
69. Bremner JD, Vythilingam M, Vermetten E, Southwick SM, McGlashan T, Nazeer A, et al. MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. *Am J Psychiatry*. 2003;160(5):924–32. DOI: [10.1176/appi.ajp.160.5.924](https://doi.org/10.1176/appi.ajp.160.5.924). PMID: 12727697
70. Bremner JD, Ortergo RV, Campanella C, Nye JA, Davis LL, Fani N, et al. Neural correlates of PTSD in women with childhood sexual abuse with and without PTSD and response to paroxetine treatment: a placebo-controlled, double-blind trial. *J Affect Disord Rep*. 2023;14:100615. DOI: [10.1016/j.jadr.2023.100615](https://doi.org/10.1016/j.jadr.2023.100615). PMID: 38088987; PMCID: [PMC10715797](https://pubmed.ncbi.nlm.nih.gov/PMC10715797/)
71. Cha J, Greenberg T, Song I, Simpson HB, Posner J, Mujica-Parodi LR. Abnormal hippocampal structure and function in clinical anxiety and comorbid depression. *Hippocampus*. 2016;26(5):545–53. DOI: [10.1002/hipo.22566](https://doi.org/10.1002/hipo.22566). PMID: 26743454; PMCID: [PMC4837065](https://pubmed.ncbi.nlm.nih.gov/PMC4837065/)
72. Gaddum JH. Tryptamine receptors. *J Physiol*. 1953;119(2–3):363–8. DOI: [10.1113/jphysiol.1953.sp004851](https://doi.org/10.1113/jphysiol.1953.sp004851). PMID: 13035757; PMCID: [PMC1392807](https://pubmed.ncbi.nlm.nih.gov/PMC1392807/)
73. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. *Br J Pharmacol Chemother*. 1957;12(3):323–8. DOI: [10.1111/j.1476-5381.1957.tb00142.x](https://doi.org/10.1111/j.1476-5381.1957.tb00142.x). PMID: 13460238; PMCID: [PMC1509685](https://pubmed.ncbi.nlm.nih.gov/PMC1509685/)
74. Marin P, Bécamel C, Chaumont-Dubel S, Vandermoere F, Bockaert J, Claeysen S. Classification and signaling characteristics of 5-HT receptors: toward the concept of 5-HT receptosomes. *Handbook of Behavioral Neuroscience*. London, United Kingdom: Elsevier; 2020. p. 91–120.
75. Halberstadt AL, Nichols DE. Serotonin and serotonin receptors in hallucinogen action. *Handbook of Behavioral Neuroscience*. London, United Kingdom: Elsevier; 2020. p. 843–63.
76. Weber ET, Andrade R. Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice. *Front Neurosci*. 2010;4:36. DOI: [10.3389/fnins.2010.00036](https://doi.org/10.3389/fnins.2010.00036). PMID: 20802802; PMCID: [PMC2928707](https://pubmed.ncbi.nlm.nih.gov/PMC2928707/)
77. Andrade R. Serotonergic regulation of neuronal excitability in the prefrontal cortex. *Neuropharmacology*. 2011;61(3):382–6. DOI: [10.1016/j.neuropharm.2011.01.015](https://doi.org/10.1016/j.neuropharm.2011.01.015). PMID: 21251917; PMCID: [PMC3110517](https://pubmed.ncbi.nlm.nih.gov/PMC3110517/)
78. Blier P, de Montigny C. Electrophysiological investigation of the adaptive response of the 5-HT system to the administration of 5-HT1A receptor agonists. *J Cardiovasc Pharmacol*. 1990;15(Suppl 7):S42–48. PMID: 1702486
79. Di Giovanni G, Chagraoui A, Bharatiya R, De Deurwaerdère P. Serotonergic control of excitability: from neuron to networks. *Handbook of Behavioral Neuroscience*. London, United Kingdom: Elsevier; 2020. p. 197–215.
80. Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, El Mestikawy S, et al. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. *J Comp Neurol*. 1996;365(2):289–305. DOI: [10.1002/\(SICI\)1096-9861\(19960205\)365:2<289::AID-CNE7>3.0.CO;2-1](https://doi.org/10.1002/(SICI)1096-9861(19960205)365:2<289::AID-CNE7>3.0.CO;2-1). PMID: 8822171
81. Santana N. Expression of serotonin1a and serotonin2a receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. *Cereb Cortex*. 2004;14(10):1100–9. DOI: [10.1093/cercor/bhh070](https://doi.org/10.1093/cercor/bhh070). PMID: 15115744
82. Deakin JF, Graeff FG. 5-HT and mechanisms of defence. *J Psychopharmacol*. 1991;5(4):305–15. DOI: [10.1177/026988119100500414](https://doi.org/10.1177/026988119100500414). PMID: 22282829
83. Paul ED, Lowry CA. Functional topography of serotonergic systems supports the Deakin/Graeff hypothesis of anxiety and affective disorders. *J Psychopharmacol*. 2013;27(12):1090–106. DOI: [10.1177/0269881113490328](https://doi.org/10.1177/0269881113490328). PMID: 23704363
84. Weisstaub NV, Zhou M, Lira A, Lambe E, González-Maeso J, Hornung JP, et al. Cortical 5-HT 2A receptor signaling modulates anxiety-like behaviors in mice. *Science*. 2006;313(5786):536–40. DOI: [10.1126/science.1123432](https://doi.org/10.1126/science.1123432). PMID: 16873667
85. Christianson JP, Ragole T, Amat J, Greenwood BN, Strong PV, Paul ED, et al. 5-Hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress. *Biol Psychiatry*. 2010;67(4):339–45. DOI: [10.1016/j.biopsych.2009.09.011](https://doi.org/10.1016/j.biopsych.2009.09.011). PMID: 19914601; PMCID: [PMC3278236](https://pubmed.ncbi.nlm.nih.gov/PMC3278236/)
86. Zhang G, Ásgeirsdóttir HN, Cohen SJ, Munchow AH, Barrera MP, Stackman RW. Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. *Neuropharmacology*. 2013;64:403–13. DOI: [10.1016/j.neuropharm.2012.06.007](https://doi.org/10.1016/j.neuropharm.2012.06.007). PMID: 22722027; PMCID: [PMC3477617](https://pubmed.ncbi.nlm.nih.gov/PMC3477617/)
87. Stiedl O, Misane I, Spiess J, Ögren SO. Involvement of the 5-HT1A receptors in classical fear conditioning in C57BL/6J mice. *J Neurosci*. 2000;20(22):8515–27. DOI: [10.1523/JNEUROSCI.20-22-08515.2000](https://doi.org/10.1523/JNEUROSCI.20-22-08515.2000). PMID: 11069959; PMCID: [PMC6773161](https://pubmed.ncbi.nlm.nih.gov/PMC6773161/)
88. Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacology*. 2021;46(3):537–44. DOI: [10.1038/s41386-020-00883-6](https://doi.org/10.1038/s41386-020-00883-6). PMID: 33059356; PMCID: [PMC8027607](https://pubmed.ncbi.nlm.nih.gov/PMC8027607/)
89. Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. *Elife*. 2018;7:e35082. DOI: [10.7554/eLife.35082](https://doi.org/10.7554/eLife.35082). PMID: 30355445; PMCID: [PMC6202055](https://pubmed.ncbi.nlm.nih.gov/PMC6202055/)
90. Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. *Biol Psychiatry*. 2012;72(11):898–906. DOI: [10.1016/j.biopsych.2012.04.005](https://doi.org/10.1016/j.biopsych.2012.04.005). PMID: 22578254
91. Tueting PA, Metz J, Rhoades BK, Boutros NN. Pharmacologic challenge in ERP research. *Ann N Y Acad Sci*. 1992;658(1):223–55. DOI: [10.1111/j.1749-6632.1992.tb22847.x](https://doi.org/10.1111/j.1749-6632.1992.tb22847.x). PMID: 1497260
92. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. *J Cogn Neurosci*. 2005;17(10):1497–508. DOI: [10.1162/089892905774597191](https://doi.org/10.1162/089892905774597191). PMID: 16269092
93. Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. *Eur Neuropsychopharmacol*. 2016;26(4):756–66. DOI: [10.1016/j.euroneuro.2016.01.005](https://doi.org/10.1016/j.euroneuro.2016.01.005). PMID: 26875114
94. Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. *Proc Natl Acad Sci U S A*. 2021;118(17):e2022489118. DOI: [10.1073/pnas.2022489118](https://doi.org/10.1073/pnas.2022489118). PMID: 33850049; PMCID: [PMC8092378](https://pubmed.ncbi.nlm.nih.gov/PMC8092378/)
95. Pic-Taylor A, da Motta LG, de Moraes JA, Junior WM, de Fátima Andrade Santos A, Campos LA, et al. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat. *Behav Processes*. 2015;118:102–10. DOI: [10.1016/j.beproc.2015.05.004](https://doi.org/10.1016/j.beproc.2015.05.004). PMID: 26049017
96. Cameron LP, Benson CJ, Dunlap LE, Olson DE. Effects of N, N-dimethyltryptamine on rat behaviors relevant to anxiety and depression. *ACS Chem Neurosci*. 2018;9(7):1582–90. DOI: [10.1021/acscchemneuro.8b00134](https://doi.org/10.1021/acscchemneuro.8b00134). PMID: 29664276; PMCID: [PMC7196340](https://pubmed.ncbi.nlm.nih.gov/PMC7196340/)
97. Jones NT, Zahid Z, Grady SM, Sultan ZW, Zheng Z, Razidlo J, et al. Transient elevation of plasma glucocorticoids supports psilocybin-induced anxiolysis in mice. *ACS Pharmacol Transl Sci*. 2023;6(8):1221–31. DOI: [10.1021/acspstsc.3c00123](https://doi.org/10.1021/acspstsc.3c00123). PMID: 37588757; PMCID: [PMC10425994](https://pubmed.ncbi.nlm.nih.gov/PMC10425994/)
98. Fortunato JJ, Réus GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F, et al. Acute harmine administration induces antidepressant-like effects and increases BDNF levels in the rat hippocampus. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33(8):1425–30. DOI: [10.1016/j.pnpbp.2009.07.021](https://doi.org/10.1016/j.pnpbp.2009.07.021). PMID: 19632287
99. Favaro VM, Yonamine M, Soares JCK, Oliveira MGM. Effects of long-term ayahuasca administration on memory and anxiety in rats. *PLoS One*. 2015;10(12):e0145840. DOI: [10.1371/journal.pone.0145840](https://doi.org/10.1371/journal.pone.0145840). PMID: 26716991; PMCID: [PMC4696664](https://pubmed.ncbi.nlm.nih.gov/PMC4696664/)
100. Cameron LP, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N, N-Dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. *ACS Chem Neurosci*. 2019;10(7):3261–70. DOI: [10.1021/acscchemneuro.8b00692](https://doi.org/10.1021/acscchemneuro.8b00692). PMID: 30829033; PMCID: [PMC6639775](https://pubmed.ncbi.nlm.nih.gov/PMC6639775/)
101. Nasehi M, Jamshidi-Mehr M, Khakpai F, Zarrindast MR. Possible involvement of CA1 5-HT1B/1D and 5-HT2A/2B/2C receptors in harmaline-induced amnesia. *Pharmacol Biochem Behav*. 2014;125:70–7. DOI: [10.1016/j.pbb.2014.08.007](https://doi.org/10.1016/j.pbb.2014.08.007). PMID: 25181578
102. Libânio TC, Eufrásio RA, Niigaki SS, Peres FF, Silva RH, Zuardi AW, et al. Harmine impairs memory performance of treated rats and nontreated cagemates. *Exp Clin Psychopharmacol*. 2022;30(6):751–9. DOI: [10.1037/pha0000525](https://doi.org/10.1037/pha0000525). PMID: 34735205
103. Du Y, Li Y, Zhao X, Yao Y, Wang B, Zhang L, et al. Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. *Chin Med J (Engl)*. 2023;136(24):2983. DOI: [10.1097/CM9.0000000000002647](https://doi.org/10.1097/CM9.0000000000002647). PMID: 37000971; PMCID: [PMC10752473](https://pubmed.ncbi.nlm.nih.gov/PMC10752473/)
104. Ishikawa R, Fukushima H, Frankland PW, Kida S. Hippocampal neurogenesis enhances prompt forgetting of remote fear memory after hippocampal reactivation by retrieval. *Elife*. 2016;5:e17464. DOI: [10.7554/eLife.17464](https://doi.org/10.7554/eLife.17464). PMID: 27669409; PMCID: [PMC5036964](https://pubmed.ncbi.nlm.nih.gov/PMC5036964/)



105. Sekeres MJ, Winocur G, Moscovitch M, Anderson JAE, Pishdadian S, Wojtowicz JM, et al. Changes in patterns of neural activity underlie a time-dependent transformation of memory in rats and humans. *Hippocampus*. 2018; 28(10):745–64. DOI: [10.1002/hipo.23009](https://doi.org/10.1002/hipo.23009). PMID: 29989271
106. Suzuki A, Fukushima H, Mukawa T, Toyoda H, Wu LJ, Zhao MG, et al. Upregulation of CREB-mediated transcription enhances both short- and long-term memory. *J Neurosci*. 2011;31(24):8786–802. DOI: [10.1523/JNEUROSCI.3257-10.2011](https://doi.org/10.1523/JNEUROSCI.3257-10.2011). PMID: 21677163; PMCID: [PMC6622960](https://pubmed.ncbi.nlm.nih.gov/PMC6622960/)
107. McLean CP, Levy HC, Miller ML, Tolin DF. Exposure therapy for PTSD: a meta-analysis. *Clin Psychol Rev*. 2022;91:102115. DOI: [10.1016/j.cpr.2021.102115](https://doi.org/10.1016/j.cpr.2021.102115). PMID: 34954460
108. Burbach L, Brémault-Phillips S, Nijdam MJ, McFarlane A, Vermetten E. Treatment of posttraumatic stress disorder: a state-of-the-art review. *Curr Neuropsychopharmacol*. 2023;22(4):557. DOI: [10.2174/1570159X21666230428091433](https://doi.org/10.2174/1570159X21666230428091433). PMID: 37132142; PMCID: [PMC10845104](https://pubmed.ncbi.nlm.nih.gov/PMC10845104/)
109. Smid GE, van der Meer CAI, Olff M, Nijdam MJ. Predictors of outcome and residual symptoms following trauma-focused psychotherapy in police officers with posttraumatic stress disorder. *J Trauma Stress*. 2018;31(5):764–74. DOI: [10.1002/jts.22328](https://doi.org/10.1002/jts.22328). PMID: 30338583
110. Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. *Braz J Psychiatry*. 2022;44(3):298. DOI: [10.1590/1516-4446-2021-2317](https://doi.org/10.1590/1516-4446-2021-2317). PMID: 35293520; PMCID: [PMC9169481](https://pubmed.ncbi.nlm.nih.gov/PMC9169481/)
111. Lanius RA, Brand B, Vermetten E, Frewen PA, Spiegel D. The dissociative subtype of posttraumatic stress disorder: rationale, clinical and neurobiological evidence, and implications: dissociative subtype of PTSD. *Depress Anxiety*. 2012;29(8):701–8. DOI: [10.1002/da.21889](https://doi.org/10.1002/da.21889). PMID: 22431063
112. Lanius RA, Williamson PC, Bluhm RL, Densmore M, Boksman K, Neufeld RWJ, et al. Functional connectivity of dissociative responses in posttraumatic stress disorder: a functional magnetic resonance imaging investigation. *Biol Psychiatry*. 2005;57(8):873–84. DOI: [10.1016/j.biopsych.2005.01.011](https://doi.org/10.1016/j.biopsych.2005.01.011). PMID: 15820708
113. Ebner-Priemer UW, Mauchnik J, Kleindienst N, Schmahl C, Peper M, Rosenthal MZ, et al. Emotional learning during dissociative states in borderline personality disorder. *J Psychiatry Neurosci*. 2009;34(3):214. PMID: 19448852; PMCID: [PMC2674975](https://pubmed.ncbi.nlm.nih.gov/PMC2674975/)
114. Riba J, Romero S, Grasa E, Mena E, Carrió I, Barbanoj MJ. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. *Psychopharmacology (Berl)*. 2006;186(1):93–8. DOI: [10.1007/s00213-006-0358-7](https://doi.org/10.1007/s00213-006-0358-7). PMID: 16575552
115. Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JAS, Hallak JEC, et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. *PLoS One*. 2015;10(2):e0118143. DOI: [10.1371/journal.pone.0118143](https://doi.org/10.1371/journal.pone.0118143). PMID: 25693169; PMCID: [PMC4334486](https://pubmed.ncbi.nlm.nih.gov/PMC4334486/)
116. Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. *Neuropsychopharmacology*. 2016;41(11):2638–46. DOI: [10.1038/npp.2016.82](https://doi.org/10.1038/npp.2016.82). PMID: 27249781; PMCID: [PMC5026740](https://pubmed.ncbi.nlm.nih.gov/PMC5026740/)
117. Mueller F, Lenz C, Dolder PC, Harder S, Schmid Y, Lang UE, et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. *Transl Psychiatry*. 2017;7(4):e1084. DOI: [10.1038/tp.2017.54](https://doi.org/10.1038/tp.2017.54). PMID: 28375205; PMCID: [PMC5416695](https://pubmed.ncbi.nlm.nih.gov/PMC5416695/)
118. Sanchez TA, Ramos LR, Araujo F, Schenberg EE, Yonamine M, Lobo I, et al. Emotion regulation effects of Ayahuasca in experienced subjects during implicit aversive stimulation: an fMRI study. *J Ethnopharmacol*. 2024;320:117430. DOI: [10.1016/j.jep.2023.117430](https://doi.org/10.1016/j.jep.2023.117430). PMID: 37979818
119. Rossi GN, Rocha JM, Osório FL, Bousso JC, Ona G, Silveira GDO, et al. Interactive effects of ayahuasca and cannabidiol in social cognition in healthy volunteers: a pilot, proof-of-concept, feasibility, randomized-controlled trial. *J Clin Psychopharmacol*. 2023;43(4):339–49. DOI: [10.1097/JCP.0000000000001691](https://doi.org/10.1097/JCP.0000000000001691). PMID: 37335211
120. Rocha JM, Rossi GN, De Lima Osório F, Bousso JC, De Oliveira Silveira G, Yonamine M, et al. Effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers: a pilot, proof-of-concept, randomized controlled trial. *J Clin Psychopharmacol*. 2021;41(3):267–74. DOI: [10.1097/JCP.0000000000001396](https://doi.org/10.1097/JCP.0000000000001396). PMID: 33843820
121. Bousso JC, González D, Fondelva S, Cutchet M, Fernández X, Barbosa PCR, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. *PLoS One*. 2012;7(8):e42421. DOI: [10.1371/journal.pone.0042421](https://doi.org/10.1371/journal.pone.0042421). PMID: 22905130; PMCID: [PMC3414465](https://pubmed.ncbi.nlm.nih.gov/PMC3414465/)
122. Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V, Cruz APM. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. *J Ethnopharmacol*. 2007;112(3):507–13. DOI: [10.1016/j.jep.2007.04.012](https://doi.org/10.1016/j.jep.2007.04.012). PMID: 17532158
123. Aicher HD, Mueller MJ, Dornbier DA, Suay D, Elsner C, Wicki I, et al. Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects. *Front Psychiatry*. 2024;14:1302559. DOI: [10.3389/fpsy.2023.1302559](https://doi.org/10.3389/fpsy.2023.1302559). PMID: 38264636; PMCID: [PMC10804806](https://pubmed.ncbi.nlm.nih.gov/PMC10804806/)
124. Liu F, Wu J, Gong Y, Wang P, Zhu L, Tong L, et al. Harmine produces antidepressant-like effects via restoration of astrocytic functions. *Prog Neuropsychopharmacol Biol Psychiatry*. 2017;79:258–67. DOI: [10.1016/j.pnpbp.2017.06.012](https://doi.org/10.1016/j.pnpbp.2017.06.012). PMID: 28625859
125. de Almeida RN, de Menezes Galvão AC, da Silva FS, Santos Silva EAD, Palhano-Fontes F, Maia-de-Oliveira JP, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. *Front Psychol*. 2019;10:1234. DOI: [10.3389/fpsyg.2019.01234](https://doi.org/10.3389/fpsyg.2019.01234). PMID: 31231276; PMCID: [PMC6558429](https://pubmed.ncbi.nlm.nih.gov/PMC6558429/)
126. Cho JH, Deisseroth K, Bolshakov VV. Synaptic encoding of fear extinction in mPFC-amygdala circuits. *Neuron*. 2013;80(6):1491–507. DOI: [10.1016/j.neuron.2013.09.025](https://doi.org/10.1016/j.neuron.2013.09.025). PMID: 24290204; PMCID: [PMC3872173](https://pubmed.ncbi.nlm.nih.gov/PMC3872173/)
127. Santini E, Muller RU, Quirk GJ. Consolidation of Extinction Learning Involves Transfer from NMDA-Independent to NMDA-Dependent Memory. *J Neurosci*. 2001;21(22):9009. DOI: [10.1523/JNEUROSCI.21-22-09009.2001](https://doi.org/10.1523/JNEUROSCI.21-22-09009.2001). PMID: 11698611; PMCID: [PMC6762277](https://pubmed.ncbi.nlm.nih.gov/PMC6762277/)
128. Peters J, Dieppa-Perea LM, Melendez LM, Quirk GJ. Induction of fear extinction with hippocampal-infralimbic BDNF. *Science*. 2010;328(5983):1288–90. DOI: [10.1126/science.1186909](https://doi.org/10.1126/science.1186909). PMID: 20522777; PMCID: [PMC3570764](https://pubmed.ncbi.nlm.nih.gov/PMC3570764/)
129. Bloodgood DW, Sugam JA, Holmes A, Kash TL. Fear extinction requires infralimbic cortex projections to the basolateral amygdala. *Transl Psychiatry*. 2018;8(1):1–11. DOI: [10.1038/s41398-018-0106-x](https://doi.org/10.1038/s41398-018-0106-x). PMID: 29507292; PMCID: [PMC5838104](https://pubmed.ncbi.nlm.nih.gov/PMC5838104/)
130. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT_{2A} receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. *J Neurosci*. 1997;17(8):2785–95. DOI: [10.1523/JNEUROSCI.17-08-02785.1997](https://doi.org/10.1523/JNEUROSCI.17-08-02785.1997). PMID: 9092600; PMCID: [PMC6573109](https://pubmed.ncbi.nlm.nih.gov/PMC6573109/)
131. Morales-García JA, Calleja-Conde J, Lopez-Moreno JA, Alonso-Gil S, Sanz-SanCristobal M, Riba J, et al. N, N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. *Transl Psychiatry*. 2020;10(1):331. DOI: [10.1038/s41398-020-01011-0](https://doi.org/10.1038/s41398-020-01011-0). PMID: 32989216; PMCID: [PMC7522265](https://pubmed.ncbi.nlm.nih.gov/PMC7522265/)
132. Aghajanian GK, Foote WE, Sheard MH. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. *Science*. 1968;161(3842):706–8. DOI: [10.1126/science.161.3842.706](https://doi.org/10.1126/science.161.3842.706). PMID: 4874578
133. Lowry CA, Hollis JH, de Vries A, Pan B, Brunet LR, Hunt JRF, et al. Identification of an immune-responsive mesolimbocortical serotonergic system: potential role in regulation of emotional behavior. *Neuroscience*. 2007;146(2):756–72. DOI: [10.1016/j.neuroscience.2007.01.067](https://doi.org/10.1016/j.neuroscience.2007.01.067). PMID: 17367941; PMCID: [PMC1868963](https://pubmed.ncbi.nlm.nih.gov/PMC1868963/)
134. Graeff FG, Quintero S, Gray JA. Median raphe stimulation, hippocampal theta rhythm and threat-induced behavioral inhibition. *Physiol Behav*. 1980;25(2):253–61. DOI: [10.1016/0031-9384\(80\)90213-9](https://doi.org/10.1016/0031-9384(80)90213-9). PMID: 6447883
135. Carhart-Harris R, Nutt D. Serotonin and brain function: a tale of two receptors. *J Psychopharmacol*. 2017;31(9):1091–120. DOI: [10.1177/0269881117725915](https://doi.org/10.1177/0269881117725915). PMID: 28858536; PMCID: [PMC5606297](https://pubmed.ncbi.nlm.nih.gov/PMC5606297/)

Publisher's note: Genomic Press maintains a position of impartiality and neutrality regarding territorial assertions represented in published materials and affiliations of institutional nature. As such, we will use the affiliations provided by the authors, without editing them. Such use simply reflects what the authors submitted to us and it does not indicate that Genomic Press supports any type of territorial assertions.



Open Access. This article is licensed to Genomic Press under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). The license mandates: (1) Attribution: Credit must be given to the original work, with a link to the license and notification of any changes. The acknowledgment should not imply licensor endorsement. (2) NonCommercial: The material cannot be used for commercial purposes. (3) NoDerivatives: Modified versions of the work cannot be distributed. (4) No additional legal or technological restrictions may be applied beyond those stipulated in the license. Public domain materials or those covered by statutory exceptions are exempt from these terms. This license does not cover all potential rights, such as publicity or privacy rights, which may restrict material use. Third-party content in this article falls under the article's Creative Commons license unless otherwise stated. If use exceeds the license scope or statutory regulation, permission must be obtained from the copyright holder. For complete license details, visit <https://creativecommons.org/licenses/by-nc-nd/4.0/>. The license is provided without warranties.